ReviewDermatology research and practice2016
Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature.
Review in Dermatology research and practice, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 63 citations in OpenAlex.
- Dabrafenib-Induced Cutaneous Eruptions in a Patient With Langerhans Cell Histiocytosis.Case reports in dermatological medicine · 2026Article
- Functional proteoform group deconvolution reveals a broader spectrum of ibrutinib off-targets.Nature communications · 2025Article
- The role of tribbles homolog 2 in cell proliferation.Cell communication and signaling : CCS · 2025Review
- The Olive Oil Monophenolic Secoiridoid Ligstroside Aglycone Suppresses Melanoma Progression by Targeting the BRAF Signaling Pathway.Molecules (Basel, Switzerland) · 2025Article
- Navigating the complexity of BRAF mutations in non-small cell lung cancer: current insights and future prospects.Multidisciplinary respiratory medicine · 2024Article
- Toxicities from BRAF and MEK Inhibitors: Strategies to Maximize Therapeutic Success.Current oncology reports · 2024Review
- Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders.Haematologica · 2024Article
- Oral Adverse Events Associated with BRAF and MEK Inhibitors in Melanoma Treatment: A Narrative Literature Review.Healthcare (Basel, Switzerland) · 2024Review
- Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies.Cancers · 2023Review
- Successful Dabrafenib Desensitization Protocols in a Patient with Metastatic Melanoma.Medicina (Kaunas, Lithuania) · 2022Article
- Erdheim-Chester Disease Successfully Treated with Front-Line Single-Agent Dabrafenib.The American journal of case reports · 2022Article
- Loss of TACC1 variant25 inducing cell proliferation and suppressing autophagy in head and neck squamous carcinoma.Cell death discovery · 2021Article
- Article
- Interpretable deep recommender system model for prediction of kinase inhibitor efficacy across cancer cell lines.Scientific reports · 2021Article
- Upregulation of TRIB2 by Wnt/β-catenin activation in BRAFCancer chemotherapy and pharmacology · 2021Article
- Oral Manifestations in Melanoma Patients Treated with Target or Immunomodulatory Therapies.Journal of clinical medicine · 2021Review
- Treatment beyond progression and locoregional approaches in selected patients withDrugs in context · 2021Review
- Oral mucositis: the hidden side of cancer therapy.Journal of experimental & clinical cancer research : CR · 2020Review
- Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials.BMC cancer · 2020Article
- [Supportive therapy and management of side effects in dermato-oncology].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of melanoma has recently been increasing. BRAF mutations have been found in 40-60% of melanomas. The increased activity of BRAF V600E leads to the activation of downstream signaling through the mitogen-activated protein kinase (MAPK) pathway, which plays a key role as a regulator of cell growth, differentiation, and survival. The use of BRAF inhibitors in metastatic melanoma with BRAF mutation ensures clinical improvement of the disease. Vemurafenib and dabrafenib are two selective BRAF inhibitors approved by the Food and Drug Administration (FDA). Both drugs are well tolerated and successfully used in clinical practice. However, some adverse reactions have been reported in patients in the course of treatment. Cutaneous side effects are the most common adverse events among them with a broad spectrum. Both the case reports and several original clinical trials reported cutaneous reactions during the treatment with BRAF inhibitors. In this review, the common cutaneous side effects of BRAF inhibitors in the treatment of metastatic melanoma with BRAF V600E mutation were reviewed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.